Studies on psychotropic drugs. XVII. Effects of 3-chloro-5-(3-(4-piperidino-4-carbamoyl-piperidino)-propyl)-10,11-dihydro-5(H)-dibenz-(b,f)-azepine dihydrochloride monohydrate (Y-4153) on the metabolism of biogenic amines.
D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism*; D001792:Blood Platelets / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002219:Carbamates / Q000494:pharmacology; D002395:Catecholamines / Q000096:biosynthesis; D002746:Chlorpromazine / Q000378:metabolism; D003984:Dibenzazepines / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D005260:Female; D007099:Imipramine / Q000378:metabolism; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D014149:Tranquilizing Agents / Q000494:pharmacology*
D001679:Biogenic Amines; D002219:Carbamates; D002395:Catecholamines; D003984:Dibenzazepines; D010880:Piperidines; D014149:Tranquilizing Agents; D012701:Serotonin; D008995:Monoamine Oxidase; D007099:Imipramine; D002746:Chlorpromazine; D004298:Dopamine